<?xml version="1.1" encoding="utf-8"?>
<article xsi:noNamespaceSchemaLocation="http://jats.nlm.nih.gov/publishing/1.1/xsd/JATS-journalpublishing1-mathml3.xsd" dtd-version="1.1" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><front><journal-meta><journal-id journal-id-type="publisher-id">MRP</journal-id><journal-title-group><journal-title>Medical Research and Practice</journal-title></journal-title-group><issn>2993-9690</issn><eissn>2993-9704</eissn><publisher><publisher-name>Art and Design</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.61369/MRP.10707</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title>复方磺胺甲恶唑的联合抗菌机制</title><url>https://artdesignp.com/journal/MRP/2/11/10.61369/MRP.10707</url><author>程晓雪,杨立会,王艳玲,赵雨润,宋倩男</author><pub-date pub-type="publication-year"><year>2024</year></pub-date><volume>2</volume><issue>11</issue><history><date date-type="pub"><published-time>2024-11-20</published-time></date></history><abstract>复方磺胺甲恶唑是一种广谱抗菌药物，由磺胺类和甲恶唑类药物以固定比例组成，其联合抗菌作用机制基于对细菌叶酸代谢途径的协同抑制，阻断细菌的核酸合成。本文从理论基础入手，分析其作用靶点、代谢抑制路径及应对细菌耐药性的策略，进一步探讨其对细菌代谢链和基因调控的系统性影响，以及对宿主微生态平衡的调节作用，为合理用药提供理论支持。</abstract><keywords>复方磺胺甲恶唑,抗菌机制,协同效应,细菌代谢,耐药性</keywords></article-meta></front><body/><back><ref-list><ref id="B1" content-type="article"><label>1</label><element-citation publication-type="journal"><p>[1]辛浩洋.磺胺甲恶唑对污水生物脱氮除磷的影响及机制研究[J].工业用水与废水,2022,53(06):6-10.[2]赵冬雪,刘璐,穆迎春,等.磺胺甲恶唑高效降解菌群的多样性分析和降解微生物的分离表征[J].生物技术进展,2021,11(02):196-203.[3]Hannah M ,Deirdre C ,Raf D . Role of process parameters in the degradation of sulfamethoxazole by heat-activated peroxymonosulfate oxidation: Radical identification and elucidation of the degradation mechanism [J]. Chemical Engineering Journal, 2021, 422[4]Chiara B ,Sebastien R ,Emma T , et al. Impact of sulfamethoxazole on a riverine microbiome [J]. Water Research, 2021, 201 117382-117382.[5]Putecova K ,Nedbalcova K ,Bartejsova I , et al. Experimental determination of&amp;Acirc; the pharmacokinetic properties of&amp;Acirc; trimethoprim and sulfamethoxazole combination in&amp;Acirc; the blood serum of&amp;Acirc; broiler chickens [J]. Veterin&amp;Atilde;&amp;iexcl;rn&amp;Atilde;medic&amp;Atilde;na, 2021, 66 (6):[6]曹江波,魏小莉.利福平联合复方磺胺甲恶唑治疗CA-MRSA肺炎1例[J].当代医学,2020,26(12):116-118.[7]方龙香,宋超,范立民,等.基于正交实验设计的磺胺甲恶唑在渔业水体中的消解动态规律[J].中国农学通报,2019,35(27):146-152.[8]赵纳. 复方磺胺甲恶唑联合常规雾化治疗支气管结核疗效及安全性分析 [J]. 数理医药学杂志, 2015, 28 (08): 1186-1187.[9]刘碧翠,覃仕鹤,余新华. 复方磺胺甲恶唑联合常规雾化治疗支气管结核的临床疗效观察 [J]. 中国生化药物杂志, 2014, 34 (04): 155-156+160.[10]丁建英. 复方磺胺甲恶唑、甲硝唑及氟哌酸联合治疗压疮的效果观察 [J]. 云南医药, 2012, 33 (06): 612-613.[11]李合基,黄雁,李成建.药物所致便秘[J].中国误诊学杂志.2006,(19).[12]吴丹,郑徽,李明爽,等.中国2018-2021年百日咳流行病学特征[J].中国疫苗和免疫.2022,28(6).[13]胡付品,郭燕,朱德妹,等.2021年CHINET中国细菌耐药监测[J].中国感染与化疗杂志.2022,22(5).[14]谢兴凤,刘小青,代春梅,等.耐碳青霉烯酶肺炎克雷伯菌的流行病学特点及药物敏感性分析[J].四川医学.2023,44(3).[15]乔燕,夏丞垚,李永凯,等.粘细菌Corallococcus sp.strain EGB及其培养发酵液的安全性评估[J].微生物学报.2022,62(1).</p><pub-id pub-id-type="doi"/></element-citation></ref></ref-list></back></article>
